Workflow
易明医药拟转让23%股份,58同城姚劲波将成实控人
002826Tibet Aim Pharm. (002826) 新京报· Xin Jing Bao·2025-06-04 12:15

Core Viewpoint - The acquisition of shares in Yiming Pharmaceutical by Beijing Fuhai marks a significant change in control, with the new actual controller being Yao Jinbo, founder of 58.com, aiming to enhance the company's business development and asset quality [1][3]. Group 1: Share Transfer Details - Beijing Fuhai plans to acquire 43,855,883 shares of Yiming Pharmaceutical from Gao Fan at a price of 15.10 yuan per share, totaling 662 million yuan, which represents 23.00% of the company's total shares [1]. - Following the completion of this transaction, the controlling shareholder will shift from Gao Fan to Beijing Fuhai, with Yao Jinbo becoming the new actual controller [1]. Group 2: Company Performance - Yiming Pharmaceutical has experienced a decline in revenue over the past two years, with projected revenues of 667 million yuan and 652 million yuan for 2023 and 2024, reflecting year-on-year decreases of 22.14% and 2.27% respectively [2]. - The net profit attributable to the parent company for 2023 and 2024 is expected to be 15.39 million yuan and 45.93 million yuan, showing a significant year-on-year change of -65.14% and 198.50% respectively [2]. - In Q1 2025, Yiming Pharmaceutical reported a revenue of 149 million yuan, down 7.41% year-on-year, and a net profit of 18.79 million yuan, down 32.64% year-on-year [2]. Group 3: Performance Commitment - Gao Fan has made performance commitments for Yiming Pharmaceutical, ensuring that the company achieves a minimum revenue of 600 million yuan for each fiscal year from 2025 to 2027, and a net profit of no less than 30 million yuan [2]. - For 2028, the commitments include maintaining positive figures for net profit, total assets, and net assets, along with compliance with specific regulations [2]. Group 4: Market Reaction - Following the announcement of the share transfer, Yiming Pharmaceutical's stock was suspended from trading on May 27, 2025, and upon resuming trading on June 4, it opened at a limit-up price of 13.40 yuan per share, reflecting a 10.02% increase [3].